Abstract
Apart from resistance to drugs, which varies in the different human tumor types and still requires much basic research, experience arising from chemotherapeutic management of patients with cancers allows us to evidence some crucial points, the investigation and solution of which may improve clinical results in potentially chemoresponsive tumors. One of these is the variability in sensitivity to the same drugs of clinically similar tumors; another deals with the unforeseeable recurrence of tumors that have shown similar responses to first-line treatment.
Supported in part by Grant PFCCN n° 83.00946.96
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Auer G, Tribukait B (1980) Comparative single cell and flow DNA analysis in aspiration biopsies from breast carcinomas. Acta Pathol Microbiol Scand 88: 355–358
Bichee P, Poulsen HS, Andersen J (1982) Estrogen receptor and ploidy of human mammary carcinoma. Cancer 50: 1771–1774
Bonadonna G (1974) Chemoterapia dei linfomi linfocitico e istiocitico. In: Bucalossi P, Veronesi U, Bonadonna G, Emanuelli H (eds) I linfomi maligni. Casa Editrice Ambrosiana, Milan, pp 269–275
Bonadonna G, Valagussa P, Tancini G, Di Fronzo G (1980) Estrogen-receptor status and response to chemotherapy in early and advanced breast cancer. Cancer Chemother Pharmacol 4: 37–41
Costa A, Bonadonna G, Villa E, Valagussa P, Silvestrini R (1981) Labeling index as a prognostic marker in non-Hodgkin’s lymphomas. J Natl Cancer Inst 66: 1–5
Daidone MG, Silvestrini R, Di Fronzo G (1982) Prognostic relevance of cell kinetics, alone or in association with estrogen receptor (ER) status, in operable and advanced breast cancers. Breast Cancer Res Treat 2: 277
Daidone MG, Silvestrini R, Zaffaroni N, Sanfilippo O, Varini M (1983) Reliability of a short-term antimetabolic assay in predicting drug sensitivity of breast cancers. In: Stool BA (ed) Reviews on endocrine-related cancer. Stuart Pharmaceuticals, Division of ICI American Inc.
Diamond LW, Braylan RC (1980) Flow analysis of DNA content and cell size in non-Hodgkin’s lymphoma. Cancer Res 40: 703–712
Diamond LW, Nathwani BN, Rappaport H (1982) Flow cytometry in the diagnosis and classification of malignant lymphoma and leukemia. Cancer 50: 1122–1135
Di Fronzo G, Bertuzzi A, Ronchi E (1978) An improved criterion for the evaluation of estrogen receptor binding data in human breast cancer. Tumori 64: 259–266
Durie BG, Salmon SE, Moon TE (1980) Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55: 364–372
Fleiss JL (1973) Statistical methods for rates and proportions. Wiley series in probability and mathematical statistics. Wiley, New York
Gentili C, Sanfilippo O, Silvestrini R (1981) Cell proliferation and its relationship to clinical features and relapse in breast cancer. Cancer 48: 974–979
Hoogstratten B, Fabian C (1979) A reappraisal of single drugs in advanced breast cancer. Cancer Clin Trials, Summer 101–109
Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ (1978) Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299: 1330–1334
Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HMT, Aitken SC, Warren R (1978) The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298: 1223–1228
Meyer JS, Hixon B (1979) Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices. Cancer Res 39: 4042–4047
Meyer JS, Rao BR, Stevens SC, White WL (1977) Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication. Cancer 40: 2290–2298
Meyer JS, Friedman E, McCrate MM, Bauer WC (1983) Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51: 1879–1886
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 35: 1–39
Rappaport H (1966) Tumors of the hematopoietic system. In: Atlas of tumor pathology, sect III, fasc 8. Armed Forces Institute of Pathology, Washington DC, pp 91–166
Sanfilippo O, Daidone MG, Costa A, Canetta R, Silvestrini R (1981) Estimation of differential in vitro sensitivity of non-Hodgkin lymphomas to anticancer drugs. Eur J Cancer 17: 217–226
Silvestrini R, Piazza R, Riccardi A, Rilke F (1977) Correlation of cell kinetic findings with morphology of non-Hodgkin’s malignant lymphomas. J Natl Cancer Inst 58: 499–504
Silvestrini R, Daidone MG, Di Fronzo G (1979) Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer 44: 665–670
Silvestrini R, Costa A, Del Bino G, Mazzini G (1982) Flow cytofluorometric determination of DNA characteristics in non-Hodgkin’s lymphomas. Proceedings, 13th International Cancer Congress, Seattle, September 8–15
Silvestrini R, Sanfilippo O, Daidone MG (1983) An attempt to use incorporation of radioactive nucleic acid precursors to predict clinical response. In: Dendy PP, Hill BT (eds) Human tumour drug sensitivity testing in vitro. Techniques and clinical applications. Academic Press, London, pp 281–290
Steiner R, Stewart JF, Knight RK, Rubens RD (1981) The contribution of vincristine to Adriamycin in the treatment of advanced breast cancer (abstract). UICC Conference on clinical oncology, Lausanne, October 28–31
Tubiana M, Pejovich MJ, Renaud A, Contesso G, Chavaudra N, Gioanni J, Malaise EP (1981) Kinetic parameters and the course of the disease in breast cancer. Cancer 47: 937–943
Wasserman TH, Comis RL, Goldsmith M, Handelsman H, Penta JS, Slavik M, Soper WT, Carter SK (1975) Tabular analysis of the clinical chemotherapy of solid tumors. Cancer Chemother Rep 6: 399–419
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Silvestrini, R., Sanfilippo, O., Daidone, M.G., Zaffaroni, N. (1984). Predictive Relevance for Clinical Outcome of In Vitro Sensitivity Evaluated Through Antimetabolic Assay. In: Hofmann, V., Berens, M.E., Martz, G. (eds) Predictive Drug Testing on Human Tumor Cells. Recent Results in Cancer Research, vol 94. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82295-7_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-82295-7_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-82297-1
Online ISBN: 978-3-642-82295-7
eBook Packages: Springer Book Archive